Publications

Citations via Google Scholar

Ahmed S, Ahmed O, Anderson D, Beck G, Chalchal HI, Dwernychuk L, Gitlin J, Hammond A, Iqbal M, Lim J, Pati S, Sari N, Shaw J, Souied O, Wall C, Zaidi A, Moser M. (2021) Systemic therapy with a loco-regional treatment in patients with locally advanced pancreatic cancer: The SMART study. Journal of Clinical Oncology 2021 39:3_suppl, TPS445. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.TPS445?af=R

Ahmed S, Anderson D, Chalchal HI, Dwernychuk L, Gill D, Gitlin J, Hammond A, Kanthan R, Le D, Lim J, Rakheja R, Sari N, Vizeacoumar FJ, Zaidi A, Moser M. (2021) Conversion from unresectable to resectable liver metastases in real-world patients with liver-only metastatic colorectal cancer (mCRC) treated with FOLFOXIRI plus bevacizumab: The Conversion trial. Journal of Clinical Oncology 2021 39:3_suppl, TPS147. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.TPS147

Anderson, DH (2020) Book chapter title: Luminal A breast cancer resistance mechanisms and emerging treatments, in “Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance”. Edited by Freywald A, Vizeacoumar FJ. Elsevier Publishing. Volume 12, 1st Edition. Hardcover ISBN: 9780128213100; eBook ISBN: 9780128213117. Imprint: Academic Press. Published Date: 18th November 2020. https://www.sciencedirect.com/science/article/pii/B9780128213100000103

Miah S, Bagu E, Goel R, Ogunbolude Y, Dai C, Ward A, Vizeacoumar FS, Davies G, Vizeacoumar FJ, Anderson D, Lukong KE (2019) Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells. BMC Cancer 2019 19:78 (IF 3.3) PMID: 30651078; https://www.ncbi.nlm.nih.gov/pubmed/30651078

Marshall JDS, Whitecross DE, Mellor P, Anderson DH (2019) Impact of p85α Alterations in Cancer. BioMolecules 2019 Jan 15;9(1), 29 (IF 4.5) PMID: 30650664; https://www.ncbi.nlm.nih.gov/pubmed/30650664

Marshall JDS, Mellor P, Ruan X, Whitecross DE, Moore SA, Anderson DH (2018) Insight into the p85a – PTEN interaction and lipid binding properties of the p85a BH domain. Oncotarget. 2018; 9:36975-36992 (IF 8.7) PMID: 30561929; https://www.ncbi.nlm.nih.gov/pubmed/30651929

Toosi BM, El Zawily A, Truitt L, Shannon M, Allonby O, Babu M, DeCoteau J, Mousseau D, Ali M, Freywald T, Gall A, Vizeacoumar FS, Kirzinger MW, Geyer CR, Anderson DH, Kim T, Welm AL, Siegel P, Vizeacoumar FJ, Kusalik A, Freywald A (2018) EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours. Oncogene. Apr 27. doi: 10.1038/s41388-018-0228-x. [Epub ahead of print] (IF 8.5) PMID: 29700392; https://www.ncbi.nlm.nih.gov/pubmed/29700392

Mellor P, Marshall JDS, Ruan X, Whitecross DE, Ross RL, Knowles MA, Moore SA, Anderson DH (2018) Patient-derived mutations within the N-terminal domains of p85α impact PTEN or Rab5 binding and regulation. Sci Rep. May 8;8(1):7108. doi: 10.1038/s41598-018-25487-5. (IF 5.5) PMID: 29740032; https://www.ncbi.nlm.nih.gov/pubmed/29740032

Whitecross DE, Anderson DH (2017) Identification of the Binding Sites on Rab5 and p110beta Phosphatidylinositol 3-kinase. Sci Rep. Nov 23;7(1):16194. doi: 10.1038/s41598-017-16029-6. (IF 5.5) PMID: 29170408; https://www.ncbi.nlm.nih.gov/pubmed/29170408

Wu Q, Li Z, Mellor P, Zhou Y, Anderson DH, Liu Q (2017) The role of PTEN - HCV core interaction in hepatitis C virus replication. Sci Rep. 2017 Jun 16;7(1):3695. doi: 10.1038/s41598-017-03052-w. (IF 5.5) PMID: 28623358; https://www.ncbi.nlm.nih.gov/pubmed/28623358

Smith SE, Mellor P, Ward AK, Kendall S, McDonald M, Vizeacoumar FS, Vizeacoumar FJ, Napper S, Anderson DH (2017) Molecular characterization of breast cancer cell lines through multiple omic approaches. Breast Cancer Res. Jun 5;19(1):65. doi: 10.1186/s13058-017-0855-0. (IF 5.87) PMID: 28583138; https://www.ncbi.nlm.nih.gov/pubmed/28583138

Cunningham CE, Li S, Vizeacoumar FS, Bhanumathy KK, Lee JS, Parameswaran S, Furber L, Paul JM, Templeton SD, Shukla H, Boyd F, Alli N, Mousseau D, Geyer R, Bonham K, Anderson DH, Yan J, Yu-Lee L-Y, Weaver BA, Uppalapati M, Ruppin E, Sablina A, Freywald A and Vizeacoumar FJ (2016) Therapeutic relevance of the protein phosphatase 2A in cancer. Oncotarget. Sep 20;7(38):61544-61561. (IF 8.67)  PMID: 27557495; https://www.ncbi.nlm.nih.gov/pubmed/27557495

Paul JM, Toosi B, Vizeacoumar FS, Bhanumathy KK, Li Y, Gerger C, El Zawily A, Freywald T, Anderson DH, Mousseau D, Kanthan R, Zhang Z, Vizeacoumar FJ and Freywald A (2016) Targeting synthetic lethality between SRC kinase and the EPHB6 receptor may benefit cancer treatment.  Oncotarget. Aug 2;7(31):50027-50042. (IF 8.67) PMID: 27418135; https://www.ncbi.nlm.nih.gov/pubmed/27418135

Beyrakhova KA, van Straaten K, Li L, Boniecki MT, Anderson DH and Cygler M (2016) Structural and functional investigations of the effector protein LpiR1 from Legionella pneumophila. J Biol Chem. Jul 22;291(30):15767-77. (IF 4.57) PMID: 27226543; https://www.ncbi.nlm.nih.gov/pubmed/27226543

Ward AK, Mellor P, Smith S, Kendall S, Just NA, Vizeacoumar FS, Sarker S, Phillips Z, Alvi R, Saxena A, Vizeacoumar FJ, Carlsen SA, and Anderson DH (2016) Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.  Breast Cancer Res. Jan 25;18(1):12. (IF 5.87) PMID: 26810754; https://www.ncbi.nlm.nih.gov/pubmed/26810754

Satram-Maharaj T, Nyarko JNK, Kuski K, Fehr K, Truit L, Freywald A, Lukong E, Anderson DH and Mousseau DD (2014) The monoamine oxidase-A inhibitor clorgyline promotes features supporting an apparent mesenchymal-to-epithelial transition in the MDA-MB-231 breast cancer cell line. Cellular Signalling, Aug 22; 26(12):2621-2632. (IF 4.47) PMID: 25152370

Allonby O, El Zawily AM, Freywald T, Mousseau DD, Chlan J, Anderson D, Benmerah A, Sidhu V, Babu M, DeCoteau J and Freywald A (2014) Kinase-dead EphB6 receptor loses Hsp90 aid and is efficiently downregulated following stimulation.  Cellular Signalling, Aug 23; 26(12):2645-2657. (IF 4.47) PMID: 25152371; https://www.ncbi.nlm.nih.gov/pubmed/25152371

Grishin AM, Cherney M, Anderson DH, Phanse S, Babu M and Cygler M (2014) NleH defines a new family of bacterial effector kinases.  Structure, 22, 250-259. (IF 6.79) PMID: 24373767; https://www.ncbi.nlm.nih.gov/pubmed/24373767

Ross RL, Burns JE, Taylor CF, Mellor P, Anderson DH and Knowles MA (2013) Identification of mutations in distinct regions of p85 alpha in urothelial cancer. PLoS One, 8, e84411. (IF 3.53) PMID: 24367658; https://www.ncbi.nlm.nih.gov/pubmed/24367658

Mellor P, Deibert L, Calvert B, Bonham K, Carlsen SA and Anderson DH (2013) CREB3L1 is a metastasis suppressor that represses expression of genes regulating metastasis, invasion and angiogenesis.  Mol Cell Biol, 33, 4985-4995. (IF 5.04) PMID: 24126059; https://www.ncbi.nlm.nih.gov/pubmed/24126059

Basquin C, Malardé V, Mellor P, Anderson DH, Meas-Yedid V, Olivo-Martin J-C, Alice Dautry-Varsat and Sauvonnet N (2013) The signalling factor PI 3-kinase is a specific regulator of the clathrin-independent dynamin-dependent endocytosis of IL-2 receptors. J Cell Sci, 126:1099-108. (IF 5.33) PMID: 23345407

Meng S, Zhang M, Pan W, Li Z, Anderson DH, Ge B and Wang C (2012) Tyrosines 303/343/353 within the Sprouty-related domain of Spred2 are essential for its interaction with p85 and inhibitory effect on Ras/ERK activation.  Int J Biochem Cell Biol, 44, 748-758. (IF 4.24) PMID: 22305891

Mellor P, Furber LA, Nyarko JNK, and Anderson DH (2012) Multiple Roles for the p85a Isoform in the Regulation and Function of PI3K Signalling and Receptor Trafficking. Biochem J, 441, 23-37. (IF 4.78) PMID: 22168437; https://www.ncbi.nlm.nih.gov/pubmed/22168437

Chamberlain MD, Oberg JC, Furber LA, Poland SF, Hawrysh AD, Knafelc SM, McBride HM and Anderson DH (2010) Deregulation of Rab5 and Rab4 proteins in p85R274A-expressing cells alters PDGFR trafficking. Cell Signalling 22, 1562-1575. (IF 4.47) PMID: 20570729; https://www.ncbi.nlm.nih.gov/pubmed/20570729

Anderson DH (2010) p85 plays a critical role in controlling flux through the PI3K/PTEN signaling axis through dual regulation of both p110 (PI3K) and PTEN. Cell Cycle, 9, 2055-2056.  (IF 5.01) PMID: 20505341

Li Y, Lu X, Li J, Bérubé N, Giest K-L, Liu Q, Anderson DH, and Zhou Y (2010) Genetic engineered, biarsenical labelled influenza virus allows visualization of viral NS1 protein in living cells. J. Virol, 84, 7204-7213. (IF 4.65) PMID: 20463066

Chagpar RB, Links PH, Pastor MC, Furber LA, Hawrysh AD, Chamberlain MD and Anderson DH (2010) Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase.  Proc Natl Acad Sci USA, 107, 5471-5476. (IF 9.81) PMID: 20212113; https://www.ncbi.nlm.nih.gov/pubmed/20212113

Torres VA, Mielgo A, Barila D, Anderson DH and Stupack D (2008) Caspase 8 promotes peripheral localization and activation of Rab5. J. Biol. Chem., 283, 36280-36289. (IF 4.77) PMID: 18974049

Li Y, Anderson DH, Liu Q and Zhou Y (2008) Mechanism of influenza A virus NS1 protein interaction with the p85b, and not the p85a, subunit of PI3K and upregulation PI3K activity.  J. Biol. Chem, 283, 23397-23409. (IF 4.77) PMID: 18534979

Chamberlain MD, Chan T, Oberg JC, Hawrysh AD, James KM, Saxena A, Xiang J and Anderson DH (2008) Disrupted RabGAP function of the p85 subunit of phosphatidylinositol 3`-kinase results in cell transformation.  J Biol Chem, 283, 15861-15868. (IF 4.77) PMID: 18387942; https://www.ncbi.nlm.nih.gov/pubmed/18387942